Needle Free Vaccination Articles & Analysis: Older
9 news found
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced the publication of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. ...
The sublingual COVID-19 vaccine uses sublingual mucosal delivery technology to deliver the vaccine to the mucous membrane. ...
Australian biotechnology company, Vaxxas Pty Ltd (Vaxxas), in collaboration with the University of Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, has completed a study assessing the usability and acceptability of its novel High-Density Microarray Patch (HD-MAP) to administer vaccines. The HD-MAP is Vaxxas’ proprietary vaccine ...
The data confirm the potential of V-306 for prophylaxis against Respiratory Syncytial Virus (RSV) infection, possibly using a convenient needle-free method of vaccination. Despite the substantial health and economic burden caused by RSV-associated illness, no vaccine is available. The first of two manuscripts has been published ...
Meissa is developing MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and at-risk, older adults from respiratory syncytial virus (RSV). ...
The Article ‘A Total Meltdown‘ highlights how next generation vaccination technologies such as ImplaVax® needle-free, thermally stable unit solid dose vaccination platform could make a material impact on the ease of future deployment and reduce or eliminate the burden of cold chain ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live ...
Enesi Pharma recently hosted a crew from Asahi TV, one of Japan’s leading TV channels, at its Oxford, UK facility to talk about the potential of its ImplaVax® solid dose needle-free vaccination technology. The conversation coincided with the approval of the Pfizer/BioNTech COVID-19 vaccine Comirnaty® in Japan and ...
Meissa is developing MV-012-968, an intranasal (needle-free), live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV. ...